We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Peripheral Metabolic Effects of Somatostatin

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01062529
Recruitment Status : Completed
First Posted : February 4, 2010
Last Update Posted : January 21, 2013
The Ministry of Science, Technology and Innovation, Denmark
Information provided by (Responsible Party):
University of Aarhus

January 28, 2010
February 4, 2010
January 21, 2013
October 2009
February 2010   (Final data collection date for primary outcome measure)
Plasma levels of glucose [ Time Frame: 3 months ]
Same as current
Complete list of historical versions of study NCT01062529 on ClinicalTrials.gov Archive Site
  • GH signalling [ Time Frame: one year ]
  • Serum levels of free fatty acids (FFA) [ Time Frame: one year ]
Same as current
Not Provided
Not Provided
Peripheral Metabolic Effects of Somatostatin
Peripheral Metabolic Effects of Intra Arterial Somatostatin Infusion in Healthy Controls
The aim of this study is to investigate peripheral effects of Somatostatin on glucose metabolism and growth hormone (GH) signalling in healthy men. Eight subjects will be enrolled. The hypothesis is that Somatostatin infusion reverses insulin resistance caused by GH.
Not Provided
Not Provided
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single (Participant)
Primary Purpose: Basic Science
  • Acromegaly
  • Growth Hormone Deficiency
  • Diabetes
Drug: Somatostatin
4 h of 150 microgram infusion
Experimental: somatostatin
Intervention: Drug: Somatostatin
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
February 2010
February 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • BMI < 27 kg/m2
  • Written informed consent
  • Healthy

Exclusion Criteria:

  • Any disease
  • Any use of medications
  • Present or previous malignancy
  • Alcohol dependency
  • Allergy to trial medication
Sexes Eligible for Study: Male
18 Years to 50 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
University of Aarhus
University of Aarhus
The Ministry of Science, Technology and Innovation, Denmark
Principal Investigator: Jens Otto L Jørgensen, Professor
University of Aarhus
January 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP